But the guidance was written for a world where off-label use is a secondary market phenomenon
As stated in the CY 2025 OPPS/ASC final rule with comment period (89 FR 93932 through 93938), given the unique nature of these therapies, we do not believe they function as integral, ancillary, supportive, dependent, or adjunctive to any of the current primary C-APC services
Chris McCurdy My guest is Dr
Here, we present a case of colonic ischemia likely due to semaglutide use
Observational studies have suggested that weight reduction can improve lymphedema symptoms and reduce limb volume in obese patients with the condition, though the quality of evidence remains limited
Clinical trials show 15 to 22% average body weight reduction